United States - English - NLM (National Library of Medicine)

zoetis inc. - ceftiofur hydrochloride (unii: 6822a07436) (ceftiofur - unii:83jl932i1c) - ceftiofur 500 mg in 10 ml - spectramast® dc ceftiofur hydrochloride sterile suspension is indicated for the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with staphylococcus aureus , streptococcus dysgalactiae , and streptococcus uberis . spectramast® dc ceftiofur hydrochloride sterile suspension has been proven effective against staphylococcus aureus , streptococcus dysgalactiae , and streptococcus uberis . as with all drugs, the use of spectramast® dc sterile suspension is contraindicated in animals previously found to be hypersensitive to the drug.

United States - English - NLM (National Library of Medicine)

zoetis inc. - ceftiofur hydrochloride (unii: 6822a07436) (ceftiofur - unii:83jl932i1c) - ceftiofur 125 mg in 10 ml - spectramast® lc (ceftiofur intramammary suspension) sterile suspension is indicated for use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, streptococcus dysgalactiae , and escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and streptococcus dysgalactiae . as with all drugs, the use of spectramast® lc sterile suspension is contraindicated in animals previously found to be hypersensitive to the drug.

Israel - English - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for injection - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure.hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start.the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.

European Union - English - EMA (European Medicines Agency)

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera and immunoglobulins, - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure. hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start. the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.,

Australia - English - Department of Health (Therapeutic Goods Administration)

leica microsystems pty ltd - 58850 - spectral-domain optical coherence tomography system - the ophthalmic imaging system is intended to acquire, process, display and save depth-resolved images of ocular tissue microstructure using spectral domain optical coherence tomography (sdoct). the ophthalmic imaging system is indicated for use as an aid in the visualization of physiologic and pathologic conditions of the eye through non-contact optical imaging. it is indicated for use on patient populations from premature and neonatal infants to adult. the system is indicated for use in supine imaging, mounted to a surgical microscope, with cooperative patients or patients under anesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

heidelberg engineering pty ltd - 58850 - spectral-domain optical coherence tomography system - the spectralis is a non-contact ophthalmic diagnostic imaging device for: viewing the posterior segment of the eye, including two- and three-dimensional imaging; cross-sectional imaging (spectralis hra+oct and spectralis oct); fundus imaging; fluorescence imaging (fluorescein angiography, indocyanine greenangiography; spectralis hra+oct, spectralis hra); autofluorescence imaging (spectralis hra+oct, spectralis hra and spectralis oct with bluepeak); performing measurements of ocular anatomy and ocular lesions. it is indicated as an aid in the detection and management of various ocular diseases, including age-related macular degeneration; macular oedema; diabetic retinopathy; retinal and choroidal vascular diseases; glaucoma and for viewing geographic atrophy as well as changes in the eye that result from neurodegenerative diseases. the spectralis oct angiography module is indicated as an aid in the visualization of vascular structures of the retina and choroid. the spectralis hra+oct and spectralis oct include

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 160 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

speclipse australia pty ltd - 63442 - dermatological laser-induced breakdown spectroscopy system - spectra-scope? is an objective spectroscopic system designed as a tool to aid medical professionals in the assessment of suspicious skin lesions for skin cancers. spectra-scope? is not meant to be used to make a definitive diagnosis or to replace the expert opinion of a medical professional. it is intended to provide information that may be useful to the medical professionals in the biopsy decision. spectra-scope? is indicated for the evaluation of clinically suspicious lesions for skin cancers; basal cell carcinoma, squamous cell carcinoma, melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

speclipse australia pty ltd - 63442 - dermatological laser-induced breakdown spectroscopy system - spectra-scope? standalone is an objective spectroscopic system designed as a tool to aid medical professionals in the assessment of suspicious skin lesions for skin cancers. spectra-scope? standalone is not meant to be used to make a definitive diagnosis or to replace the expert opinion of a medical professional. it is intended to provide information that may be useful to the medical professionals in the biopsy decision. spectra-scope? standalone is indicated for the evaluation of clinically suspicious lesions for skin cancers; basal cell carcinoma, squamous cell carcinoma, melanoma.